Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A

Kenji Tsujikawa, Yukihiko Dan, Kiyoko Nogawa, Hitoshi Sato, Yasuhiko Yamada, Hideyasu Murakami, Hisakazu Ohtani, Yasufumi Sawada, Tatsuji Iga

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The distribution of domperidone (DOM), a peripheral dopamine D2 receptor antagonist, to the brain is restricted by P-glycoprotein (P-gp) at the blood-brain barrier (BBB) and for this reason, DOM rarely causes parkinsonian symptoms, such as extrapyramidal side effects (EPS), unlike other dopamine D2 antagonists. In this study, we aimed to investigate whether cyclosporin A (CsA), a P-gp inhibitor, potentiates EPS induced by DOM. The intensity of EPS was assessed in terms of the duration of catalepsy in mice. D1, D2 and mACh receptor occupancies at the striatum were measured in vivo and in vitro. Moreover, the distribution of DOM to the brain was investigated by using an in situ brain perfusion technique. The intensity of DOM-induced catalepsy was significantly potentiated by the coadministration of CsA. The in vivo occupancies of D1, D2 and mACh receptors, as well as the brain distribution of DOM, were increased by CsA. These results suggest that CsA increases the brain distribution of DOM by inhibiting P-gp at the BBB, and potentiates catalepsy by increasing the occupancies of the D1 and D2 receptors. The risk of DOM-induced parkinsonism may be enhanced by the coadministration of CsA.

Original languageEnglish
Pages (from-to)105-114
Number of pages10
JournalBiopharmaceutics and Drug Disposition
Volume24
Issue number3
DOIs
Publication statusPublished - 2003 Apr
Externally publishedYes

Fingerprint

Domperidone
Catalepsy
P-Glycoprotein
Cyclosporine
Brain
Blood-Brain Barrier
Parkinsonian Disorders
Perfusion

Keywords

  • Catalepsy
  • Cyclosporin A
  • Domperidone
  • Dopamine receptor
  • Receptor occupancies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Tsujikawa, K., Dan, Y., Nogawa, K., Sato, H., Yamada, Y., Murakami, H., ... Iga, T. (2003). Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. Biopharmaceutics and Drug Disposition, 24(3), 105-114. https://doi.org/10.1002/bdd.343

Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. / Tsujikawa, Kenji; Dan, Yukihiko; Nogawa, Kiyoko; Sato, Hitoshi; Yamada, Yasuhiko; Murakami, Hideyasu; Ohtani, Hisakazu; Sawada, Yasufumi; Iga, Tatsuji.

In: Biopharmaceutics and Drug Disposition, Vol. 24, No. 3, 04.2003, p. 105-114.

Research output: Contribution to journalArticle

Tsujikawa, K, Dan, Y, Nogawa, K, Sato, H, Yamada, Y, Murakami, H, Ohtani, H, Sawada, Y & Iga, T 2003, 'Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A', Biopharmaceutics and Drug Disposition, vol. 24, no. 3, pp. 105-114. https://doi.org/10.1002/bdd.343
Tsujikawa, Kenji ; Dan, Yukihiko ; Nogawa, Kiyoko ; Sato, Hitoshi ; Yamada, Yasuhiko ; Murakami, Hideyasu ; Ohtani, Hisakazu ; Sawada, Yasufumi ; Iga, Tatsuji. / Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. In: Biopharmaceutics and Drug Disposition. 2003 ; Vol. 24, No. 3. pp. 105-114.
@article{2dfe213da0684c3282d54cfd2bf4acd2,
title = "Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A",
abstract = "The distribution of domperidone (DOM), a peripheral dopamine D2 receptor antagonist, to the brain is restricted by P-glycoprotein (P-gp) at the blood-brain barrier (BBB) and for this reason, DOM rarely causes parkinsonian symptoms, such as extrapyramidal side effects (EPS), unlike other dopamine D2 antagonists. In this study, we aimed to investigate whether cyclosporin A (CsA), a P-gp inhibitor, potentiates EPS induced by DOM. The intensity of EPS was assessed in terms of the duration of catalepsy in mice. D1, D2 and mACh receptor occupancies at the striatum were measured in vivo and in vitro. Moreover, the distribution of DOM to the brain was investigated by using an in situ brain perfusion technique. The intensity of DOM-induced catalepsy was significantly potentiated by the coadministration of CsA. The in vivo occupancies of D1, D2 and mACh receptors, as well as the brain distribution of DOM, were increased by CsA. These results suggest that CsA increases the brain distribution of DOM by inhibiting P-gp at the BBB, and potentiates catalepsy by increasing the occupancies of the D1 and D2 receptors. The risk of DOM-induced parkinsonism may be enhanced by the coadministration of CsA.",
keywords = "Catalepsy, Cyclosporin A, Domperidone, Dopamine receptor, Receptor occupancies",
author = "Kenji Tsujikawa and Yukihiko Dan and Kiyoko Nogawa and Hitoshi Sato and Yasuhiko Yamada and Hideyasu Murakami and Hisakazu Ohtani and Yasufumi Sawada and Tatsuji Iga",
year = "2003",
month = "4",
doi = "10.1002/bdd.343",
language = "English",
volume = "24",
pages = "105--114",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A

AU - Tsujikawa, Kenji

AU - Dan, Yukihiko

AU - Nogawa, Kiyoko

AU - Sato, Hitoshi

AU - Yamada, Yasuhiko

AU - Murakami, Hideyasu

AU - Ohtani, Hisakazu

AU - Sawada, Yasufumi

AU - Iga, Tatsuji

PY - 2003/4

Y1 - 2003/4

N2 - The distribution of domperidone (DOM), a peripheral dopamine D2 receptor antagonist, to the brain is restricted by P-glycoprotein (P-gp) at the blood-brain barrier (BBB) and for this reason, DOM rarely causes parkinsonian symptoms, such as extrapyramidal side effects (EPS), unlike other dopamine D2 antagonists. In this study, we aimed to investigate whether cyclosporin A (CsA), a P-gp inhibitor, potentiates EPS induced by DOM. The intensity of EPS was assessed in terms of the duration of catalepsy in mice. D1, D2 and mACh receptor occupancies at the striatum were measured in vivo and in vitro. Moreover, the distribution of DOM to the brain was investigated by using an in situ brain perfusion technique. The intensity of DOM-induced catalepsy was significantly potentiated by the coadministration of CsA. The in vivo occupancies of D1, D2 and mACh receptors, as well as the brain distribution of DOM, were increased by CsA. These results suggest that CsA increases the brain distribution of DOM by inhibiting P-gp at the BBB, and potentiates catalepsy by increasing the occupancies of the D1 and D2 receptors. The risk of DOM-induced parkinsonism may be enhanced by the coadministration of CsA.

AB - The distribution of domperidone (DOM), a peripheral dopamine D2 receptor antagonist, to the brain is restricted by P-glycoprotein (P-gp) at the blood-brain barrier (BBB) and for this reason, DOM rarely causes parkinsonian symptoms, such as extrapyramidal side effects (EPS), unlike other dopamine D2 antagonists. In this study, we aimed to investigate whether cyclosporin A (CsA), a P-gp inhibitor, potentiates EPS induced by DOM. The intensity of EPS was assessed in terms of the duration of catalepsy in mice. D1, D2 and mACh receptor occupancies at the striatum were measured in vivo and in vitro. Moreover, the distribution of DOM to the brain was investigated by using an in situ brain perfusion technique. The intensity of DOM-induced catalepsy was significantly potentiated by the coadministration of CsA. The in vivo occupancies of D1, D2 and mACh receptors, as well as the brain distribution of DOM, were increased by CsA. These results suggest that CsA increases the brain distribution of DOM by inhibiting P-gp at the BBB, and potentiates catalepsy by increasing the occupancies of the D1 and D2 receptors. The risk of DOM-induced parkinsonism may be enhanced by the coadministration of CsA.

KW - Catalepsy

KW - Cyclosporin A

KW - Domperidone

KW - Dopamine receptor

KW - Receptor occupancies

UR - http://www.scopus.com/inward/record.url?scp=0038753950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038753950&partnerID=8YFLogxK

U2 - 10.1002/bdd.343

DO - 10.1002/bdd.343

M3 - Article

C2 - 12673668

AN - SCOPUS:0038753950

VL - 24

SP - 105

EP - 114

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 3

ER -